Local view for "http://purl.org/linkedpolitics/eu/plenary/2013-10-22-Speech-2-203-000"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20131022.25.2-203-000"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spoken text |
"Madam President, I was happy to support this report because currently the legislation that ...
I was happy to support this report because the legislation we currently have in place is not robust enough to fully ensure that low-quality, in vitro medical devices are not placed on the market. We have a duty with regard to patient safety; indeed, that is our first duty. But it is not our only duty. We also have to ensure that we have a streamlined, effective system which ensures new technologies get to market as soon as they are fully approved.
The principle of subsidiarity is also important, and the issue of prescription policies for class D devices should be at national level and not at EU level, in my view. This proposal regulates products’ safety, and not medical or other practices set out at national level.
Finally, I was fully supportive of the ALDE amendments put forward with our EPP colleagues, which aligned our position with that on the medical devices directive."@en1
|
| lpv:spokenAs | |
| lpv:unclassifiedMetadata | |
| lpv:videoURI |
Named graphs describing this resource:
The resource appears as object in 2 triples